Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
Public ClinicalTrials.gov record NCT03710564. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-masked Phase 3a Study to Assess Safety and Efficacy of Brolucizumab 6 mg q4 Weeks Compared to Aflibercept 2 mg q4 Weeks in Patients With Neovascular Age-related Macular Degeneration (nAMD) With Persistent Retinal Fluid (MERLIN)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical study was designed to compare the safety and efficacy of brolucizumab 6 mg dosed every 4 weeks to aflibercept 2 mg dosed every 4 weeks in those neovascular age-related macular degeneration (nAMD) patients with retinal fluid despite frequent anti-Vascular Endothelial Growth Factor (VEGF) injections.
Study identification
- NCT ID
- NCT03710564
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 535 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 30, 2018 (Actual)
- Primary completion
- Dec 21, 2020 (Actual)
- Completion
- Jul 1, 2021 (Actual)
- Last update posted
- Jan 30, 2023
2018 – 2021
United States locations
- U.S. sites
- 60
- U.S. states
- 25
- U.S. cities
- 54
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Phoenix | Arizona | 85016 | — |
| Novartis Investigative Site | Phoenix | Arizona | 85020 | — |
| Novartis Investigative Site | Phoenix | Arizona | 85053 | — |
| Novartis Investigative Site | Beverly Hills | California | 90211 | — |
| Novartis Investigative Site | Huntington Beach | California | 92647 | — |
| Novartis Investigative Site | Mountain View | California | 94040 | — |
| Novartis Investigative Site | Oakland | California | 94609 | — |
| Novartis Investigative Site | Oxnard | California | 93036 | — |
| Novartis Investigative Site | Palo Alto | California | 94303 | — |
| Novartis Investigative Site | Redlands | California | 92374 | — |
| Novartis Investigative Site | Sacramento | California | 95841 | — |
| Novartis Investigative Site | San Francisco | California | 94107 | — |
| Novartis Investigative Site | Santa Barbara | California | 93103 | — |
| Novartis Investigative Site | Colorado Springs | Colorado | 80909 | — |
| Novartis Investigative Site | Golden | Colorado | 80401 | — |
| Novartis Investigative Site | Deerfield Beach | Florida | 33064 | — |
| Novartis Investigative Site | Fort Lauderdale | Florida | 33308 | — |
| Novartis Investigative Site | Fort Myers | Florida | 33912-7125 | — |
| Novartis Investigative Site | Miami | Florida | 33136 | — |
| Novartis Investigative Site | Mt. Dora | Florida | 32757 | — |
| Novartis Investigative Site | Pensacola | Florida | 32503 | — |
| Novartis Investigative Site | St. Petersburg | Florida | 33711 | — |
| Novartis Investigative Site | Stuart | Florida | 34994 | — |
| Novartis Investigative Site | Marietta | Georgia | 30060 | — |
| Novartis Investigative Site | ‘Aiea | Hawaii | 96701 | — |
| Novartis Investigative Site | Wheaton | Illinois | 60187 | — |
| Novartis Investigative Site | West Des Moines | Iowa | 50266 | — |
| Novartis Investigative Site | Lenexa | Kansas | 66215 | — |
| Novartis Investigative Site | New Orleans | Louisiana | 70115-8139 | — |
| Novartis Investigative Site | West Monroe | Louisiana | 71291 | — |
| Novartis Investigative Site | Waldorf | Maryland | 20602 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02111 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02114 | — |
| Novartis Investigative Site | Springfield | Massachusetts | 01107 | — |
| Novartis Investigative Site | Royal Oak | Michigan | 48073 | — |
| Novartis Investigative Site | St Louis | Missouri | 63110 | — |
| Novartis Investigative Site | Las Vegas | Nevada | 89144 | — |
| Novartis Investigative Site | Reno | Nevada | 89502 | — |
| Novartis Investigative Site | Bloomfield | New Jersey | 07003 | — |
| Novartis Investigative Site | Toms River | New Jersey | 08755 | — |
| Novartis Investigative Site | Syracuse | New York | 13224 | — |
| Novartis Investigative Site | Charlotte | North Carolina | 28210 | — |
| Novartis Investigative Site | Cleveland | Ohio | 44122 | — |
| Novartis Investigative Site | Fairfield | Ohio | 45014 | — |
| Novartis Investigative Site | Eugene | Oregon | 97401 | — |
| Novartis Investigative Site | Kingston | Pennsylvania | 95403 | — |
| Novartis Investigative Site | Philadelphia | Pennsylvania | 19107 | — |
| Novartis Investigative Site | Germantown | Tennessee | 38138 | — |
| Novartis Investigative Site | Abilene | Texas | 79606 | — |
| Novartis Investigative Site | Austin | Texas | 78705 | — |
| Novartis Investigative Site | Austin | Texas | 78731 | — |
| Novartis Investigative Site | Austin | Texas | 78793 | — |
| Novartis Investigative Site | Fort Worth | Texas | 76102 | — |
| Novartis Investigative Site | Fort Worth | Texas | 76104 | — |
| Novartis Investigative Site | Harlingen | Texas | 78550 | — |
| Novartis Investigative Site | Houston | Texas | 77030 | — |
| Novartis Investigative Site | San Antonio | Texas | 78240 | — |
| Novartis Investigative Site | Tyler | Texas | 75701 | — |
| Novartis Investigative Site | Fairfax | Virginia | 22031 | — |
| Novartis Investigative Site | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03710564, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 30, 2023 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03710564 live on ClinicalTrials.gov.